{"name":"Akeso, Inc.","slug":"akeso","ticker":"9926","exchange":"HKEX","domain":"akesobio.com","description":"Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, and recurrent or refractory classical Hodgkin lymphoma; AK109, a PD-1 monoclonal antibody to treat G/GEJ patients; penpulimab, a PD-1 for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC); and tagitanlimab, a PD-L1 for treating recurrent or metastatic NPC. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia","hq":"Zhongshan, Guangdong, China","founded":0,"employees":"3761","ceo":"Xia Yu (Dr.)","sector":"Immuno-Oncology Biotech","stockPrice":137.5,"stockChange":-3,"stockChangePercent":-2.14,"marketCap":"$126.7B","metrics":{"revenue":3056274944,"revenueGrowth":49.6,"grossMargin":78.7,"rdSpend":0,"netIncome":-1113025024,"cash":9171627008,"dividendYield":0,"peRatio":57.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"AK101 SC patent cliff ($X.XB at risk)","drug":"AK101 SC","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"AK104(IV) patent cliff ($X.XB at risk)","drug":"AK104(IV)","type":"patent_expiry","sentiment":"negative"},{"date":"2036-06-01","label":"AK112 patent cliff ($X.XB at risk)","drug":"AK112","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":23,"colorKey":"immunology","drugs":[{"name":"AK119","genericName":"AK119","slug":"ak119","indication":"Other","status":"phase_1"},{"name":"AK129","genericName":"AK129","slug":"ak129","indication":"Other","status":"phase_1"},{"name":"AK132","genericName":"AK132","slug":"ak132","indication":"Other","status":"phase_1"},{"name":"AK101 IV","genericName":"AK101 IV","slug":"ak101-iv","indication":"Other","status":"phase_1"},{"name":"AK104 plus Carboplatin and Pemetrexed","genericName":"AK104 plus Carboplatin and Pemetrexed","slug":"ak104-plus-carboplatin-and-pemetrexed","indication":"Other","status":"phase_1"},{"name":"AK104 plus Carboplatin and paclitaxel","genericName":"AK104 plus Carboplatin and paclitaxel","slug":"ak104-plus-carboplatin-and-paclitaxel","indication":"Other","status":"phase_1"},{"name":"AK109","genericName":"AK109","slug":"ak109","indication":"Other","status":"phase_1"},{"name":"AK112 low dose","genericName":"AK112 low dose","slug":"ak112-low-dose","indication":"Other","status":"phase_2"},{"name":"AK114","genericName":"AK114","slug":"ak114","indication":"Other","status":"phase_1"},{"name":"AK115","genericName":"AK115","slug":"ak115","indication":"Other","status":"phase_1"},{"name":"AK127","genericName":"AK127","slug":"ak127","indication":"Other","status":"phase_1"},{"name":"AK127 in combination with AK112","genericName":"AK127 in combination with AK112","slug":"ak127-in-combination-with-ak112","indication":"Other","status":"phase_1"},{"name":"AK129 IV infusion","genericName":"AK129 IV infusion","slug":"ak129-iv-infusion","indication":"Other","status":"phase_1"},{"name":"AK130","genericName":"AK130","slug":"ak130","indication":"Other","status":"phase_2"},{"name":"AK135","genericName":"AK135","slug":"ak135","indication":"Other","status":"phase_1"},{"name":"AK137","genericName":"AK137","slug":"ak137","indication":"Other","status":"phase_1"},{"name":"AK138D1","genericName":"AK138D1","slug":"ak138d1","indication":"Other","status":"phase_1"},{"name":"AK139","genericName":"AK139","slug":"ak139","indication":"Other","status":"phase_2"},{"name":"AK146D1 for injection","genericName":"AK146D1 for injection","slug":"ak146d1-for-injection","indication":"Other","status":"phase_1"},{"name":"AK152","genericName":"AK152","slug":"ak152","indication":"Other","status":"phase_1"},{"name":"AK154","genericName":"AK154","slug":"ak154","indication":"Other","status":"phase_1"},{"name":"Ebronucimab","genericName":"Ebronucimab","slug":"ebronucimab","indication":"Other","status":"phase_1"},{"name":"Placebo in combination with Pembrolizumab","genericName":"Placebo in combination with Pembrolizumab","slug":"placebo-in-combination-with-pembrolizumab","indication":"Indication under investigation in Phase 3 trial (specific indication not provided)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"oncology","drugs":[{"name":"AK102","genericName":"AK102","slug":"ak102","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"AK104(IV)","genericName":"AK104(IV)","slug":"ak104-iv","indication":"Advanced or metastatic non-small cell lung cancer","status":"phase_3"},{"name":"AK101","genericName":"AK101","slug":"ak101","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"AK101 SC","genericName":"AK101 SC","slug":"ak101-sc","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"AK104 IV infusion；Chiauranib oral","genericName":"AK104 IV infusion；Chiauranib oral","slug":"ak104-iv-infusion-chiauranib-oral","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AK104 lenvatinib","genericName":"AK104 lenvatinib","slug":"ak104-lenvatinib","indication":"Metastatic renal cell carcinoma","status":"phase_2"},{"name":"AK104(SC)","genericName":"AK104(SC)","slug":"ak104-sc","indication":"Advanced non-small cell lung cancer","status":"phase_3"},{"name":"AK111","genericName":"AK111","slug":"ak111","indication":"EGFR-expressing solid tumors (in clinical development)","status":"phase_3"},{"name":"AK112 high dose","genericName":"AK112 high dose","slug":"ak112-high-dose","indication":"Advanced or metastatic solid tumors (Phase 2 evaluation)","status":"phase_2"},{"name":"AK112, Cadonilimab, nab-paclitaxel, gemcitabine","genericName":"AK112, Cadonilimab, nab-paclitaxel, gemcitabine","slug":"ak112-cadonilimab-nab-paclitaxel-gemcitabine","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"AK112, Carboplatin, Paxlitaxel","genericName":"AK112, Carboplatin, Paxlitaxel","slug":"ak112-carboplatin-paxlitaxel","indication":"Non-small cell lung cancer (in combination with carboplatin and paclitaxel)","status":"phase_3"},{"name":"AK112, Gemcitabine, Cisplatin","genericName":"AK112, Gemcitabine, Cisplatin","slug":"ak112-gemcitabine-cisplatin","indication":"Biliary tract cancer (phase 3)","status":"phase_3"},{"name":"AK112, nab-paclitaxel, gemcitabine","genericName":"AK112, nab-paclitaxel, gemcitabine","slug":"ak112-nab-paclitaxel-gemcitabine","indication":"Breast cancer","status":"phase_1"},{"name":"AK117","genericName":"AK117","slug":"ak117","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"AK117 in combination with AK112","genericName":"AK117 in combination with AK112","slug":"ak117-in-combination-with-ak112","indication":"Advanced or metastatic solid tumors (Phase 3 evaluation)","status":"phase_3"},{"name":"AK131","genericName":"AK131","slug":"ak131","indication":"Metastatic solid tumors","status":"phase_2"},{"name":"Durvalumab, Gemcitabine, Cisplatin","genericName":"Durvalumab, Gemcitabine, Cisplatin","slug":"durvalumab-gemcitabine-cisplatin","indication":"Unresectable or metastatic biliary tract cancer","status":"phase_3"},{"name":"Ivonescimab, docetaxel","genericName":"Ivonescimab, docetaxel","slug":"ivonescimab-docetaxel","indication":"Non-small cell lung cancer (Phase 3)","status":"phase_3"},{"name":"Oxaliplatin injection","genericName":"Oxaliplatin injection","slug":"oxaliplatin-injection","indication":"Colorectal cancer (metastatic and adjuvant settings)","status":"phase_3"},{"name":"Placebo+AK111","genericName":"Placebo+AK111","slug":"placebo-ak111","indication":"Solid tumors or hematologic malignancies (specific indication under Phase 3 evaluation not fully disclosed in public domain)","status":"phase_3"},{"name":"Placebo, docetaxel","genericName":"Placebo, docetaxel","slug":"placebo-docetaxel","indication":"Metastatic breast cancer","status":"phase_3"},{"name":"Tislelizumab, Carboplatin, Paxlitaxel","genericName":"Tislelizumab, Carboplatin, Paxlitaxel","slug":"tislelizumab-carboplatin-paxlitaxel","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"AK102","genericName":"AK102","slug":"ak102","phase":"phase_3","mechanism":"AK102 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"AK104(IV)","genericName":"AK104(IV)","slug":"ak104-iv","phase":"phase_3","mechanism":"AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.","indications":["Advanced or metastatic non-small cell lung cancer","Advanced hepatocellular carcinoma","Other advanced solid tumors (in development)"],"catalyst":""},{"name":"AK119","genericName":"AK119","slug":"ak119","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK129","genericName":"AK129","slug":"ak129","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK132","genericName":"AK132","slug":"ak132","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK101","genericName":"AK101","slug":"ak101","phase":"phase_3","mechanism":"AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect immune attack against PSMA-expressing cancers.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"AK101 IV","genericName":"AK101 IV","slug":"ak101-iv","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK101 SC","genericName":"AK101 SC","slug":"ak101-sc","phase":"phase_3","mechanism":"AK101 is a bispecific antibody that simultaneously engages CD3 on T cells and PSMA on tumor cells to redirect T cell killing toward PSMA-expressing cancer cells.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"AK104 IV infusion；Chiauranib oral","genericName":"AK104 IV infusion；Chiauranib oral","slug":"ak104-iv-infusion-chiauranib-oral","phase":"phase_1","mechanism":"Tyrosine kinase inhibitor","indications":["Non-small cell lung cancer","Renal cell carcinoma"],"catalyst":""},{"name":"AK104 lenvatinib","genericName":"AK104 lenvatinib","slug":"ak104-lenvatinib","phase":"phase_2","mechanism":"AK104 lenvatinib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR).","indications":["Metastatic renal cell carcinoma","Papillary thyroid carcinoma"],"catalyst":""},{"name":"AK104 plus Carboplatin and Pemetrexed","genericName":"AK104 plus Carboplatin and Pemetrexed","slug":"ak104-plus-carboplatin-and-pemetrexed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK104 plus Carboplatin and paclitaxel","genericName":"AK104 plus Carboplatin and paclitaxel","slug":"ak104-plus-carboplatin-and-paclitaxel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK104(SC)","genericName":"AK104(SC)","slug":"ak104-sc","phase":"phase_3","mechanism":"AK104 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.","indications":["Advanced non-small cell lung cancer","Advanced hepatocellular carcinoma","Other advanced solid tumors"],"catalyst":""},{"name":"AK109","genericName":"AK109","slug":"ak109","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AK111","genericName":"AK111","slug":"ak111","phase":"phase_3","mechanism":"AK111 is a bispecific antibody that simultaneously engages CD3 on T cells and EGFR on tumor cells to redirect immune attack against EGFR-expressing cancers.","indications":["EGFR-expressing solid tumors (in clinical development)"],"catalyst":""},{"name":"AK112 high dose","genericName":"AK112 high dose","slug":"ak112-high-dose","phase":"phase_2","mechanism":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and CTLA-4 to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 2 evaluation)"],"catalyst":""},{"name":"AK112 low dose","genericName":"AK112 low dose","slug":"ak112-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK112, Cadonilimab, nab-paclitaxel, gemcitabine","genericName":"AK112, Cadonilimab, nab-paclitaxel, gemcitabine","slug":"ak112-cadonilimab-nab-paclitaxel-gemcitabine","phase":"phase_1","mechanism":"CD47 antibody","indications":["Non-small cell lung cancer","Pancreatic cancer"],"catalyst":""},{"name":"AK112, Carboplatin, Paxlitaxel","genericName":"AK112, Carboplatin, Paxlitaxel","slug":"ak112-carboplatin-paxlitaxel","phase":"phase_3","mechanism":"AK112 is a bispecific antibody that simultaneously engages PD-1 on immune cells and LAG-3 on T cells to enhance anti-tumor immunity, combined with carboplatin and paclitaxel chemotherapy for direct tumor cell killing.","indications":["Non-small cell lung cancer (in combination with carboplatin and paclitaxel)","Other solid tumors (Phase 3 development)"],"catalyst":""},{"name":"AK112, Gemcitabine, Cisplatin","genericName":"AK112, Gemcitabine, Cisplatin","slug":"ak112-gemcitabine-cisplatin","phase":"phase_3","mechanism":"AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, while gemcitabine and cisplatin are chemotherapy agents that damage tumor DNA.","indications":["Biliary tract cancer (phase 3)","Non-small cell lung cancer (investigational)"],"catalyst":""},{"name":"AK112, nab-paclitaxel, gemcitabine","genericName":"AK112, nab-paclitaxel, gemcitabine","slug":"ak112-nab-paclitaxel-gemcitabine","phase":"phase_1","mechanism":"Inhibits microtubule dynamics by binding to tubulin, thereby inhibiting cell division","indications":["Breast cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"AK114","genericName":"AK114","slug":"ak114","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK115","genericName":"AK115","slug":"ak115","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK117","genericName":"AK117","slug":"ak117","phase":"phase_2","mechanism":"AK117 is a small molecule targeting the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"AK117 in combination with AK112","genericName":"AK117 in combination with AK112","slug":"ak117-in-combination-with-ak112","phase":"phase_3","mechanism":"AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.","indications":["Advanced or metastatic solid tumors (Phase 3 evaluation)"],"catalyst":""},{"name":"AK127","genericName":"AK127","slug":"ak127","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK127 in combination with AK112","genericName":"AK127 in combination with AK112","slug":"ak127-in-combination-with-ak112","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK129 IV infusion","genericName":"AK129 IV infusion","slug":"ak129-iv-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK130","genericName":"AK130","slug":"ak130","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK131","genericName":"AK131","slug":"ak131","phase":"phase_2","mechanism":"AK131 is a small molecule targeting the CD47/SIRPα axis to modulate the immune system.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"AK135","genericName":"AK135","slug":"ak135","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK137","genericName":"AK137","slug":"ak137","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK138D1","genericName":"AK138D1","slug":"ak138d1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK139","genericName":"AK139","slug":"ak139","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK146D1 for injection","genericName":"AK146D1 for injection","slug":"ak146d1-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK152","genericName":"AK152","slug":"ak152","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AK154","genericName":"AK154","slug":"ak154","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Durvalumab, Gemcitabine, Cisplatin","genericName":"Durvalumab, Gemcitabine, Cisplatin","slug":"durvalumab-gemcitabine-cisplatin","phase":"phase_3","mechanism":"This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.","indications":["Unresectable or metastatic biliary tract cancer","Potentially resectable or unresectable pancreatic cancer (in development)"],"catalyst":""},{"name":"Ebronucimab","genericName":"Ebronucimab","slug":"ebronucimab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ivonescimab, docetaxel","genericName":"Ivonescimab, docetaxel","slug":"ivonescimab-docetaxel","phase":"phase_3","mechanism":"Ivonescimab is a PD-L1/CTLA-4 bispecific antibody that blocks two immune checkpoints simultaneously, while docetaxel is a microtubule-stabilizing chemotherapy agent, together enhancing anti-tumor immunity and direct cytotoxic effects.","indications":["Non-small cell lung cancer (Phase 3)","Other solid tumors (investigational)"],"catalyst":""},{"name":"Oxaliplatin injection","genericName":"Oxaliplatin injection","slug":"oxaliplatin-injection","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell replication and induce apoptosis.","indications":["Colorectal cancer (metastatic and adjuvant settings)","Gastric cancer","Pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"Placebo in combination with Pembrolizumab","genericName":"Placebo in combination with Pembrolizumab","slug":"placebo-in-combination-with-pembrolizumab","phase":"phase_3","mechanism":"Placebo serves as a control comparator in a combination study with Pembrolizumab, a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor T-cell responses.","indications":["Indication under investigation in Phase 3 trial (specific indication not provided)"],"catalyst":""},{"name":"Placebo+AK111","genericName":"Placebo+AK111","slug":"placebo-ak111","phase":"phase_3","mechanism":"AK111 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells toward cancer cells.","indications":["Solid tumors or hematologic malignancies (specific indication under Phase 3 evaluation not fully disclosed in public domain)"],"catalyst":""},{"name":"Placebo, docetaxel","genericName":"Placebo, docetaxel","slug":"placebo-docetaxel","phase":"phase_3","mechanism":"Docetaxel is a microtubule-stabilizing agent that prevents microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Prostate cancer","Gastric cancer","Head and neck cancer"],"catalyst":""},{"name":"Tislelizumab, Carboplatin, Paxlitaxel","genericName":"Tislelizumab, Carboplatin, Paxlitaxel","slug":"tislelizumab-carboplatin-paxlitaxel","phase":"phase_3","mechanism":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells that helps to regulate the immune response. By binding to PD-1, tislelizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and other cells in the tumor microenvironment. This blockade enhances the immune response against cancer cells.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Esophageal squamous cell carcinoma","Hepatocellular carcinoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Akeso Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Akeso reported revenue of $X.X million for the fourth quarter and $Y.Y million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Akeso Announces Collaboration with Leading Cancer Research Institute","summary":"Akeso partnered with a leading cancer research institute to advance its immuno-oncology pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOOGZVOUJMWmtNaUZLckcxTjl6T2wzUHpwRHZxZUkzVk01R3hZX2QtYkRHVmJXc3VyMHhadE1rc1pnNVIzdVYwTzNCSWdxZkZuSEo1R2k0YXNfekRwS19hNS1tN3B5NGpzRC1HVnM1MmxjZnVvMWtBWTA2SW8wUU9zZUM4b05RbFVSaUVmdjVpNHdhR0VVdFBNVVRzdUpsZWxURDFGMTQxNUxjcDZVR1pmLURsTERheTBjUWZyallNb0piSjFa?oc=5","date":"2026-03-27","type":"trial","source":"BioPharma APAC","summary":"Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China - BioPharma APAC","headline":"Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNS3NzZkMwdXBIU3hTbXQ5dUlLWU00SkE4bGtKd1BtSUpYRUhyV1doc0syT2JfNElKaEEzOW0yYUJSTlJIVFkyMEktZE5yY3RXS3ZRRHp2QTd6dU9BeG1jSkZ4aWRNWXRwUmEwZmtVOWt5Q0NCb0FzLUZqaWVOcHI4WEtKM04wbkpoVFVJOXh6aV84V1A5NHZxaVYxdmNNcWRya3F2V2VneTJWN2x3UmhWYU1zdGRFZFkxVXNaLWpkMEJuYXNOdVYyR2lFT040Nzd3dVQ4M1U0S3BhZTd6WDZXSnZwbEduUVY1M3lxc2xsdjBKeURC?oc=5","date":"2026-03-04","type":"deal","source":"PR Newswire","summary":"INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) - PR Newswire","headline":"INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE04UTlJYjBMZ09keXEwQ2tnNmwzLTh4ejlNZ1d6bjByV1lIVzV1QXpid1FyWk5oTnoxQ2k2TzhNSE9TeXBoVFF3VTJnQS1RWjhIbUhicV9RN0xETVZja3EtQjJn?oc=5","date":"2026-01-29","type":"pipeline","source":"akesobio.com","summary":"Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\" - akesobio.com","headline":"Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\"","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-22","type":"pipeline","source":"simplywall.st","summary":"Akeso, Inc. (HKG:9926) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st","headline":"Akeso, Inc. (HKG:9926) May Have Run Too Fast Too Soon With Recent 26% Price Plummet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOSTBxd0lLb1ZHWGZLcEpRamRxeUdGb2lMclZudE1WV0ZwaW5BcXNqdVJSczBudlN3OWdXbzZ4QXF2aXpYbTlheE1fMGdBNDBxYkFQVjRWRnp5NkJsbnFwNXJsWU55bjhlU2ZqNGg3OEw0Sno3enBmVDE2aXBkRWVfVkQ2dzRlMTdzd0drNkMwMDdpQWc?oc=5","date":"2025-09-04","type":"pipeline","source":"thebambooworks.com","summary":"Akeso shares take a hit despite surging sales of cancer drugs - thebambooworks.com","headline":"Akeso shares take a hit despite surging sales of cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNaXdIbmRFbXBKbFo4UjBCdmJNQWVERXVERjJFdzhldUF1X2d4U1FUQU1YQWpBY0lZV28xY0lCdS1RQlUtY010VDZTMlI4Ym5RTXJwRkZ6YkgxQUlLTDY2ZEhkMThVVTV3U0NDb2JVT0xOd1R1czZFMXBfclFObHhfanF6b24yM0ZJQzdNT29VV0xjX3RRb2lzd3VQRmRwVGZ6dHVva0gtLVFBVVdPYW56ckEwekFfcF9OTFd3d0lWVXhTSmozZjVhSU1hR20?oc=5","date":"2025-07-16","type":"trial","source":"BioPharma APAC","summary":"Akeso Begins Phase III Trial of Ivonescimab for Hard-to-Treat Advanced Colorectal Cancer - BioPharma APAC","headline":"Akeso Begins Phase III Trial of Ivonescimab for Hard-to-Treat Advanced Colorectal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQRFZwRGRuRHctOXZEVVZLRmtMaVZDb1QzVFlteU9IenJVVkhVS2V3cFB0V2JNNFVHQ3JYcFRxOS1WeFBhZjlzdTJQN3lBMS1qQ3ZROTN3TlZSdF9TZ0lRUGZxSTVGMzlhMXk3WWxoWFhfU0xRZ25Ib2lyeThVYklPeHFjY01qVWttU3ZlN0dHZVpzLW1IcTJRY0pTQUNubVQ2WWdSS3dpdWpISjBkel9FVw?oc=5","date":"2025-03-31","type":"pipeline","source":"Bloomberg.com","summary":"Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com","headline":"Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE9XWW85NVdQTXFEOFN1RmtOeEFLU3ZlZHBNZWYteEZFV1NvTkJULTZpcFNTT0czdnFwLVRNT0pDREUyVy1mbWNjd3JUS204OUo0YWFqODFiRWVGMDBLVWtkRFdR?oc=5","date":"2025-03-07","type":"trial","source":"akesobio.com","summary":"Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet - akesobio.com","headline":"Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBDTldQU0VENFBZYjZFR1VUNllVU0lGU1lhSVZOYW1lWGxoM2paenRjenVFOW9EdmVsM19ZTHZJSnhlOFl5SURTZWJwaVpFUk5qVnYzQWdUY2FJdw?oc=5","date":"2024-09-15","type":"pipeline","source":"TradingView","summary":"9926 Stock Price and Chart — HKEX:9926 - TradingView","headline":"9926 Stock Price and Chart — HKEX:9926","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOa2dGWEVIbVFNZl9YLWZBZ1dKV2dPMUxWOVhDcjc3dDNmNFZmdWs2RDdOdkFVX09pb3d3VXA3d1U3czdrcVJJSzdqMG9fb2VzNnd0Rks0dFBwYVNHVkNXUnFoMGpwdVBhQzFuWW5xckt3S2lkOXhhVkwwOXRkbF9Sc2J0VDFNb3k0aEk4VXc5eG9nVllZckJNT29maXQ0TDJ0cGVrQ1YtcnBJSEZwUWFNeWVkMHVBdXhQNlgtQ1J0RGdiMDZpQ3FDTVliLTItak1GaS1naHFnbVRObEMzS0J0YWQ1ZkNyRHpoTmJzbWx2d1QtU0NubGVyUUdiWTY1SUlHaGhhd0lMTVlFUDg3MjE2WUlGU3lTWk9fTC1WWl83VVBBRTBLcG5heEF6ajBXRlJ1aXdJ?oc=5","date":"2023-04-11","type":"deal","source":"PR Newswire","summary":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia - PR Newswire","headline":"Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9SM2RsM1l1aVZmcG81THYzSkI3R0FRTGVZWEhyRUF3aXdhTmg3bVR3RVJ0ampJVVBKSnNFRk9ZWHJyLXRNM3Rac3NwTWJ5eXFKZ0lPUEttd3h3LTNkU0RGUU56N1M2ellzcjdxN2l4TTZYVDd1UmFRNl9pVlFQUQ?oc=5","date":"2020-09-01","type":"pipeline","source":"marketscreener.com","summary":"Akeso, Inc.: Target Price Consensus and Analysts Recommendations | 9926 | KYG0146B1032 - marketscreener.com","headline":"Akeso, Inc.: Target Price Consensus and Analysts Recommendations | 9926 | KYG0146B1032","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE52Z3d1SGRYM0lGUkJ5SjNjS0IxMFFiM0t4MEdDSXFka3RWTDBGMFk0OVJ5MW56bEVaakp0RXM5N3VEbDJKalZqQ2RqengyUnB6Wk0tWTBR?oc=5","date":"2020-04-19","type":"pipeline","source":"Yahoo Finance Australia","summary":"Akeso, Inc. (9926.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Akeso, Inc. (9926.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"AK101 SC","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US"},{"drugName":"AK104(IV)","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US"},{"drugName":"AK112","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2036-06-01","territory":"US"}],"drugCount":45,"phaseCounts":{"phase_3":16,"phase_1":22,"phase_2":7},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology"],"financials":null,"yahoo":{"currentPrice":137.5,"previousClose":140.5,"fiftyTwoWeekHigh":179,"fiftyTwoWeekLow":60.6,"fiftyTwoWeekRange":"60.6 - 179.0","fiftyDayAverage":111.14,"twoHundredDayAverage":124.22,"beta":0.06,"enterpriseValue":123214479360,"forwardPE":57.5,"priceToBook":12.13,"priceToSales":41.44,"enterpriseToRevenue":40.31,"enterpriseToEbitda":-152.76,"pegRatio":0,"ebitda":-806590976,"ebitdaMargin":-26.4,"freeCashflow":-632246976,"operatingCashflow":-947628032,"totalDebt":4556024832,"debtToEquity":50.9,"currentRatio":5.14,"returnOnAssets":-4.6,"returnOnEquity":-14.5,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":21,"targetMeanPrice":172.99,"targetHighPrice":228.58,"targetLowPrice":114.1,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":22.1,"institutionHeldPercent":26.4,"sharesOutstanding":921143176,"floatShares":713514647,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-1.1,"epsForward":2.39,"revenuePerShare":3.38,"bookValue":11.33,"officers":[{"age":58,"name":"Dr. Yu  Xia Ph.D.","title":"Founder, CEO, President & Chairwoman"},{"age":56,"name":"Dr. Baiyong  Li Ph.D.","title":"Co-Founder, Executive VP, CSO & Executive Director"},{"age":56,"name":"Mr. Zhongmin  Wang Ph.D.","title":"Co-Founder, Senior VP & Executive Director"},{"age":48,"name":"Dr. Peng  Zhang Ph.D.","title":"Co-Founder, Senior VP & Executive Director"},{"age":54,"name":"Mr. Yu  Xia Ph.D.","title":"Senior Vice President"},{"age":48,"name":"Dr. Bing C. Wang M.B.A., Ph.D.","title":"Chief Financial Officer"},{"age":null,"name":"Dr. Mingxiu  Hu Ph.D.","title":"Senior Vice President"},{"age":null,"name":"Dr. Xinfeng  Zhang Ph.D.","title":"Senior Vice President"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.akesobio.com","phone":"86 760 8987 3998"}}